Chinese University of Hong Kong — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Chinese University of Hong Kong appears in 336 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials336

Recruiting shown60

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)NCT07568236 · lead sponsor · 2026-10-05

Duodenal pulsENDO for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver DiseaseNCT07390422 · lead sponsor · 2026-09-01

Duodenal pulsENDO as an Early Treatment for Type 2 DMNCT07376486 · lead sponsor · 2026-09-01

Duodenal-jejunal Bypass Sleeve (DJBS) for Obesity and Metabolic SyndromeNCT07675122 · lead sponsor · 2026-09-01

Endoscopic Sleeve Gastroplasty Plus Duodenal pulsENDO for Obese T2DMNCT07660445 · lead sponsor · 2026-09-01

Personalized Antiemetic Regimen According to Patients' Pharmacogenetic ProfileNCT07455955 · lead sponsor · 2026-03-31

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung ResectionNCT07159659 · lead sponsor · 2026-03-19

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung CancerNCT07379476 · lead sponsor · 2026-02-11

Adjunctive Bright Light Therapy in Adolescents With Depression and EveningnessNCT06973759 · lead sponsor · 2025-11-01

International Severe Asthma Registry_Hong KongNCT07524543 · lead sponsor · 2025-11-01

Establishment of Hong Kong Diabesity RegisterNCT07247409 · lead sponsor · 2025-10-22

Hong Kong Diabesity Register & 3-Year Trial on Integrated Care for Chinese With DiabesityNCT07039279 · lead sponsor · 2025-10-22

Impacts of HIV Treatment Regimens on Archived Drug ResistanceNCT07643948 · lead sponsor · 2025-10-01

Transcranial Pulse Stimulation for Alzheimer's DiseaseNCT07143734 · lead sponsor · 2025-07-21

Prostate Irreversible Electroporation StudyNCT06886321 · lead sponsor · 2025-06-30

The Establishment of Hong Kong Diabetes Steatotic Liver Disease RegisterNCT07437157 · lead sponsor · 2025-06-11

Telemonitoring to Optimize Medication Titration for Heart Failure: a Feasibility StudyNCT07016815 · lead sponsor · 2025-06-01

The Effect of Pulsed Electromagnetic Field Therapy on Muscle Mass and Muscle Strength in Prostate Cancer Patients Treated With Androgen Deprivation TherapyNCT07057375 · lead sponsor · 2025-06-01

Synbiotic Formula (SCV09) in Alzheimer's Disease PatientsNCT06948929 · lead sponsor · 2025-05-15

A Study on COPD Phenotypes, Endotypes and Treatable TraitsNCT06952881 · lead sponsor · 2025-05-02

Thoracic Surgery by the Medtronic Hugo™ Robotic SystemNCT06669104 · lead sponsor · 2025-05-01

Glucokinase Activator in Monogenic DiabetesNCT06976658 · lead sponsor · 2025-04-30

Isometric Resistance Exercise on Accelerated Atherosclerosis in HypertensionNCT07665034 · lead sponsor · 2025-04-16

Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic SurgeryNCT06926374 · lead sponsor · 2025-03-25

Safety of Discontinuing NSBBs in Cirrhotic Patients With Managed Primary Aetiological FactorsNCT06549673 · lead sponsor · 2025-01-20

Comparing MRI-Ultrasound Fusion and Cognitive-guided Biopsy for the Detection of csPCa: the PROFUSION TrialNCT06303622 · lead sponsor · 2025-01-08

Comparing Rezum and UroliftNCT06820606 · lead sponsor · 2025-01-01

ESG With Fundal Mucosal AblationNCT06790329 · lead sponsor · 2025-01-01

Isometric Resistance Exercise for HypertensionNCT06510998 · lead sponsor · 2025-01-01

Use of Biologics for Severe Asthma in Hong KongNCT06778746 · lead sponsor · 2024-12-26

Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney DiseaseNCT06727409 · lead sponsor · 2024-12-12

Can TElemedicine System Replace Doctor Consultations to Achieve Non-inferior Blood Pressure in Patients With Controlled HypertensionNCT06524180 · lead sponsor · 2024-10-01

Analyses of Newly Diagnosed HIV Infection in Hong KongNCT07725042 · lead sponsor · 2024-08-01

Switching of Sildenafil to Riociguat in CTEPH PatientsNCT06715280 · lead sponsor · 2024-07-25

Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence DeviceNCT06295497 · lead sponsor · 2024-07-18

Non-selective Beta-blocker in Compensated Advanced Chronic Liver DiseaseNCT06449339 · lead sponsor · 2024-07-17

To Evaluate an MRI-based Optimized Prostate Cancer Diagnostic Pathway Powered by Artificial IntelligenceNCT06360523 · lead sponsor · 2024-06-14

Differentiated Service Delivery (DSD) for People Living with HIV (PLHIV) and ComorbiditiesNCT06738134 · lead sponsor · 2024-05-01

SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes MellitusNCT06364930 · lead sponsor · 2024-03-26

A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate CancerNCT06262633 · lead sponsor · 2024-03-15

Subpectoral Plexus Block With Multi-level TPVB for Surgical Anesthesia During Primary Breast Cancer SurgeryNCT04933266 · lead sponsor · 2024-03-15

Genetic Association With Various Severities, Phenotypes and Endotypes of Asthma.NCT06196034 · lead sponsor · 2024-03-01

The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADTNCT06163924 · lead sponsor · 2023-12-10

Effect of JAK Inhibitor on Erosion Healing in RANCT05955066 · lead sponsor · 2023-12-01

Predicting Adverse Outcomes Using Machine Learning of COPD Patients in Hong KongNCT05825014 · lead sponsor · 2023-08-29

Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer DetectionNCT05443412 · lead sponsor · 2023-08-01

Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice ExperimentNCT05761093 · lead sponsor · 2022-09-07

Relationship of Airway Microbiota, Endotype and Phenotype in Adult AsthmaNCT04706988 · lead sponsor · 2021-06-22

To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong KongNCT04639791 · lead sponsor · 2021-03-01

EUS Guided Portal-systemic Pressure Gradient MeasurementNCT04633356 · lead sponsor · 2020-11-12

Archival of Human Biological Samples in CU-Med BiobankNCT04706481 · lead sponsor · 2020-01-01

Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis PatientsNCT07271420 · lead sponsor · 2020-01-01

Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With ObesityNCT07662356 · lead sponsor · 2019-12-16

Safety and Efficacy of Fecal Microbiota TransplantationNCT04014413 · lead sponsor · 2019-07-15

CUHK Brain Health Longitudinal StudyNCT03592563 · lead sponsor · 2019-07-01

Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style InterventionNCT03875625 · lead sponsor · 2019-04-01

To Identify Potential New Urine Markers for the Screening of Prostate CancerNCT03914391 · lead sponsor · 2019-01-16

Cognitive Decline in ADNCT03946930 · lead sponsor · 2018-12-13

Identifying Biomarkers in Alzheimer's DiseaseNCT05655650 · lead sponsor · 2018-09-01

Frailty in Older HIV-infected IndividualsNCT03413683 · lead sponsor · 2018-04-01

Drugs studied in this sponsor's trials

28 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Chinese University of Hong Kong as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

placebo10

atorvastatin2

denosumab2

alendronate1

apalutamide1

baricitinib 4 MG1

carvedilol1

cilostazol1

placebo RxCUI 8375 · Lead sponsor in 9 linked trial(s) · 3 currently recruiting 10 trials atorvastatin RxCUI 83367 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials denosumab RxCUI 993449 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials alendronate RxCUI 46041 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial apalutamide RxCUI 1999574 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial baricitinib 4 MG RxCUI 2588560 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial carvedilol RxCUI 20352 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial cilostazol RxCUI 21107 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial dapagliflozin RxCUI 1488564 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial dapagliflozin 10 MG Oral Tablet RxCUI 1488569 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial darbepoetin alfa RxCUI 283838 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial empagliflozin 10 MG RxCUI 1545654 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial enzalutamide RxCUI 1307298 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial fezolinetant RxCUI 2637134 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial finerenone RxCUI 2562811 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial furosemide RxCUI 4603 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial infliximab RxCUI 191831 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial insulin, regular, human RxCUI 253182 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial isosorbide dinitrate RxCUI 6058 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial liraglutide RxCUI 475968 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial methotrexate RxCUI 6851 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial pembrolizumab RxCUI 1547545 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial prednisolone RxCUI 8638 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial rabeprazole RxCUI 114979 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor309

collaborator27

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.